Ordered, immediately called back and the same day delivered the order.Very pleased with the work. Thank you for prompt and accurate work https://africarx.co.za/buy-levitra-south-africa.html great prices, delivered on the day of the order. Pleasant managers consult by phone.
Prog complet
26–29 June • World Trade & Convention Centre COS and Affiliated Societies Annual Meeting & Exhibition 2003 Scientific Program Day 2 / Jour 2 Friday, June 27 / Vendredi 27 juin Canadian Retina and Vitreous Society / Société canadienne de la rétine et du vitré Objectives: The presentations are largely of a clinical research nature. The participants will have the opportu- nity to review and discuss novel medical and surgical techniques and applications to help determine when and how they might be included in their clinical practice. Objectifs : L’exposé consiste surtout en une recherche clinique. Les participants auront l’occasion de revoir les nouvelles techniques et applications médicales et chirurgicales et d’examiner ensemble quand et comment ils pourraient les inclure dans leur pratique clinique. Guest / Invitée :Johanna M. Seddon, Boston, Massachusetts
Medical Retina I / Soins thérapeutiques de la rétine I Session chair / Présidence : Arif Samad 1030 Clinical–biochemical correlations in Oguchi’s disease
1050 Discussion 1100 Abstract A-1 Mutant frizzled-4 (FZD4) causes autosomal dominant familial exudative vitreoretinopathy with vari- able intrafamilial phenotype J. Robitaille,* M.L.E. MacDonald, A. Kaykas, L. Sheldahl, M.-P. Dube, D.L. Guernsey, B. Zheng, L.S. Siebert, A. Hoskin-Mott, M.J. Beis, S.N. Pimstone, B.S. Shastry, R.T. Moon, M.R. Hayden, Y.P. Goldberg, M.E. Samuels
1107 Abstract A-2 The effect of docosahexaenoic acid supplementation on macular function in a patient with a muta- tion in ELOVL4 I.M. MacDonald,* M. Hébert, R.J. Yau, S. Flynn, J. Jumpsen, M. Suh, M.T. Clandinin
1114 Abstract A-3 Changes in multifocal electroretinography amplitude, but not timing, secondary to chloroquine and hydroxychloroquine toxicity A. Bhargava,* S.G. Coupland, P.J. Kertes, B.C. Leonard
1121 Discussion
1130 Abstract A-4 Five-year outcomes of the Canadian proton radiation therapy experience K.E. Paton, L.A. Wittenberg*
1137 Abstract A-5 Neovascular glaucoma following proton beam radiation therapy: risk factors, monitoring and treat- ment strategies K.E. Paton,* L.A. Wittenberg
1144 Abstract A-6 Bilateral exudative retinal detachment as initial presentation of sympathetic ophthalmia C.W. Chang,* M.D.J. Greve, B.J. Hinz
1151 Discussion 1200–1330 Lunch / Déjeuner Surgical Retina / Soins chirurgicaux de la rétine Session chair / Présidence :Peter J. Kertes
1330 Retinal detachment in developing countries
1350 Discussion 1400 Abstract A-7 Posterior vitreous detachment: Is the 6-week follow-up necessary? First prize, COS/Coherent-AMT Award for Excellence in Ophthalmic Research / Premier prix d’excel- lence SCO/Coherent-AMT en recherche ophtalmique K. Hasanee,* S. Sharma
1407 Abstract A-8 The new 25-gauge sutureless vitrectomy: outcomes and complications M.-J. Fredette,* Y. Tardif, B. Cinq-Mars
1414 Abstract A-9 Massive peripapillary choroidal neovascularization: an indication for submacular surgery P.J. Kertes
1421 Discussion 1430 Abstract A-10 Visual outcome of epiretinal membrane surgery with trypan blue M. Perrier,* M. Sébag
1437 Abstract A-11 Outcome of macular hole surgery using trypan blue to facilitate delamination of the internal limiting membrane M. Perrier,* M. Sébag
1444 The etiology of macular detachment in an optic nerve pit/coloboma
1451 Discussion 1500–1530 Break / Pause Medical Retina II / Soins thérapeutiques de la rétine II Session chair / Présidence :Murray J. Erasmus
1550 Discussion 1600 Abstract A-12 Can multifocal electroretinography be used to follow patients with age-related macular degeneration after photodynamic therapy and predict the need for retreatment? M.-J. Fredette,* H. Shekavat, G. Lalonde, B. Cinq-Mars, Y. Tardif, M. Malenfant, M. Hébert
1607 Abstract A-13 Does photodynamic therapy retreatment affect electroretinal function? S.G. Coupland,* B.C. Leonard, P.J. Kertes
1614 Abstract A-14 Off-label uses of photodynamic therapy R. Varma,* M.J. Erasmus, K. Colleaux
1621 Discussion 1630 Abstract A-15 Evaluation of active and clinically resolved central serous chorioretinopathy with multifocal elec- troretinography L.A. Wittenberg,* D. Maberley
1637 Abstract A-16 Micropulsed diode laser treatment for chronic idiopathic central serous chorioretinopathy F. Ali,* N. Armogan, J. Freudenthal
1644 Abstract A-17 Focal laser treatment of retinal angiomatous proliferations guided by high-speed indocyanine green imaging T.M. Johnson,* B.M. Glaser
1651 Discussion
Risk communication: Why we need Not involving patients in important medical decisions is also understandable information ethically unjustifiable, as it is their health that is at stake. It is premature to give up on people’s ability toThis is particularly important as patients and physicians dounderstand health statistics. The example of the pill scarenot always have the same pre
Human Resources Center425 Pennsylvania Avenue Ground Covers Landscape considerations. Present day landscape If the area to be covered is large, it is generally design stresses simplicity. Often a few widely advisable to develop a broad, mass planting using spaced, carefully selected specimen plants are used one kind of plant. Occasionally, two or three kinds to create an interesting